QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, S. S Search for Related Content PubMed PubMed Citation Articles by Kim, S. S

THERAPEUTIC CONTROVERSIES

Treatment Options in Steroid-Refractory Acute Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation

Oncology Clinical Coordinator, Department of Pharmacy, The Mount Sinai Medical Center, New York, NY

Reprints: Dr. Kim, 457 W. 57th St., #612, New York, NY 10019, fax 212/426-5110, Sarasound{at}aol.com

OBJECTIVE: To evaluate the treatment options in steroid-refractory acute graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation.

DATA SOURCES: Literature was obtained by searching MEDLINE (1966-May 2007) and EMBASE (1980-May 2007).

STUDY SELECTION AND DATA EXTRACTION: All pertinent clinical trials, retrospective studies, case reports, and compassionate use studies were identified and evaluated for safety and efficacy of the pharmacologic agents.

DATA SYNTHESIS: Steroid-refractory acute GVHD is associated with high rates of morbidity and mortality. Although various pharmacologic agents have been studied in the treatment of steroid-refractory acute GVHD, no treatments have been established as a salvage therapy. Preliminary data on different pharmacologic agents have been identified and evaluated for their efficacy and tolerability in the treatment of steroid-refractory acute GVHD. The effects of the pharmacologic agents varied significantly among patients: severity of the disease, involvement of different organs, and the patient's age seem to be the major factors that affect an individual's response to drug therapy. In addition, the treatments are further challenged by the high incidence of potentially fatal opportunistic infections that occur during the therapy.

CONCLUSIONS: Selection of pharmacologic agents for the treatment of steroid-refractory acute GVHD should be based on the target organs, adverse drug reactions, and economic factors. Further studies with larger sample sizes are warranted to better understand the roles of these agents in the treatment of steroid-refractory acute GVHD.

Key Words: hematopoietic stem cell transplantation, steroid-refractory acute graft-versus-host disease

Published Online, August 7, 2007. www.theannals.com, DOI 10.1345/aph.1K179

This article has been cited by other articles:

				C. M. Lappas, P.-C. Liu, J. Linden, E. M. Kang, and H. L. Malech Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation J. Leukoc. Biol., February 1, 2010; 87(2): 345 - 354. [Abstract] [Full Text] [PDF]

				J. S Bates, A. M. Engemann, and J. M Hammond Clinical Utility of Rituximab in Chronic Graft-Versus-Host Disease Ann. Pharmacother., February 1, 2009; 43(2): 316 - 321. [Abstract] [Full Text] [PDF]